Cell Sheet for Localized Oncolytic Virus Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for multifocal hepatocellular carcinoma (HCC) face challenges such as liver toxicity from conventional therapies, high recurrence rates, and inefficiencies in delivering oncolytic adenoviruses, particularly due to systemic administration and pre-existing immunity issues.
Innovation Solution
A cell sheet with two or more layers is developed as a local gene delivery platform, where a gene delivery system is introduced into one or more layers, allowing for localized proliferation and action of oncolytic adenoviruses at tumor sites, reducing the need for high viral doses and minimizing systemic side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional systemic therapy using chemotherapeutic agents is used, then cancer cells can be targeted, but liver toxicity increases and therapeutic efficacy decreases in patients with liver dysfunction
Solution Approach 1:
The patent applies local quality by using a cell sheet that delivers oncolytic adenoviruses directly to tumor sites, creating a localized therapeutic effect. The cell sheet is implanted at the tumor location, allowing the virus to replicate and kill cancer cells in situ while minimizing exposure to healthy liver tissue, thereby reducing liver toxicity while maintaining therapeutic efficacy.
Solution Approach 2:
The cell sheet acts as an intermediary carrier that transports and releases oncolytic adenoviruses at the target site. Instead of systemic administration, the cell sheet serves as a localized delivery platform, mediating between the virus and tumor cells, enabling controlled viral release directly at the tumor microenvironment and avoiding systemic side effects.
2Reliability
If surgical resection is performed, then tumor removal is achieved, but recurrence rate remains high in multifocal HCC patients
Solution Approach 1:
The cell sheet provides continuous therapeutic action by continuously producing and releasing oncolytic adenoviruses at the tumor site. The virus replicates within the cell sheet over time, providing sustained antitumor activity that extends beyond the initial implantation, thereby preventing recurrence by continuously eliminating residual or regrowing cancer cells.
Solution Approach 2:
The cell sheet is implanted preliminarily at the tumor site to establish a localized source of oncolytic viruses before tumor recurrence can occur. This preliminary placement ensures that the therapeutic agent is already in position to act on any residual or regrowing cancer cells, preventing recurrence proactively rather than reactively.
3Area of stationary object
If oncolytic adenoviruses are administered systemically, then broad coverage is achieved, but pre-existing immunity reduces therapeutic efficacy
Solution Approach 1:
The invention uses local quality by concentrating the oncolytic adenovirus delivery at the specific tumor site through cell sheet implantation. This localized approach ensures high viral concentration where needed while avoiding systemic distribution that would trigger pre-existing immunity, thereby maintaining therapeutic efficacy without compromising coverage at the target site.
4Object-affected harmful factors
If intratumoral inoculation of virions is used, then safety is improved, but feasibility is reduced in case of multifocal tumors
Solution Approach 1:
The cell sheet serves multiple functions: it acts as a localized delivery platform, a source of continuous viral production, and a treatable unit for multifocal tumors. By implanting cell sheets at multiple tumor sites, the same therapeutic approach can be applied universally to treat multifocal HCC, maintaining safety while improving feasibility through standardized local delivery.
Data Source
AI summary
A cell sheet for gene delivery is disclosed. Unlike conventional cell sheets for tissue regeneration, the disclosed cell sheet can be used as a local gene delivery system. Particularly when a virus is used as a gene delivery system, the virus can be proliferated within the cell sheet and acts topically within a therapeutic region. Thus, the cell sheet is superior in the prevention or treatment of cancer, the prevention of cancer recurrence or cancer metastasis, particularly the treatment of multifocal tumor even though the virus dose is remarkably lowered compared to the systemic administration or intratumoral injection of the virus.